Table 8 Liquid biopsy in neverous system cancers
From: Liquid biopsy in cancer: current status, challenges and future prospects
Cancer | Liquid biomarker | Origin | Tendency | Downstream target | Function | Reference |
|---|---|---|---|---|---|---|
Glioblastoma | CTCs | Peripheral blood | up | Â | Early diagnostic biomarker, Efficacy monitoring biomarker | |
ctDNA mutation | CSF | up | Â | Early diagnostic biomarker | ||
ctDNA H3K27M mutation | CSF | up | Â | Early diagnostic biomarker, Efficacy monitoring biomarker | ||
ctDNA methylation | CSF | up | Â | Early diagnostic biomarker | ||
MCPH1 methylation | Serum | up | Â | Early diagnostic biomarker, Efficacy monitoring biomarker | ||
miR-320, miR-574-3p | Serum exosome | up | Â | Early diagnostic biomarker | ||
miRNA | CSF | up | Â | Early diagnostic biomarker | ||
PCNSL | MYD88, CARD11, CD79 mutation | CSF | up | Â | Early diagnostic biomarker | |
MYD88 | CSF | up | Â | Early diagnostic biomarker | ||
miR-200c, miR-141 | CSF exosome | down | ATP1B3, DYNC1H1, MATR3, NUCKS1, ZNF638, NUDT4, RCN2, GNPDA1, ZBTB38, DOLK | Early diagnostic biomarker, Efficacy monitoring biomarker | ||
SPP1, MARCKS, NPM1, VIM | CSF exosome | up | Â | Early diagnostic biomarker | ||
IL-10, sIL-2R | CSF | UP | Â | Early diagnostic biomarker | ||
IL-10 | CSF | up | Â | Early diagnostic biomarker | ||
Neopterin | CSF | UP | Â | Early diagnostic biomarker |
